Track record · closed signal

Bio-Techne Corporation (TECH) — closed signal from October 21, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 19, 2026 — +8.4% at the close.

Predicted vs. what happened

TECH price · publication thesis → realized outcomesplit-adjusted

$61.83 – $63.83Entry zone — fair-value band

$63.37Published — price the day we called it

$74.68Target — the price the thesis aimed for

$70.66Peak — highest point inside the window, not a realized return

$68.67Window close — end-of-window price, context only

What happened

Partial

Reached 64% of the predicted growth at its peak, without hitting the target.

At window close

+8.4%

realized, from the publication price to the last close inside the window

Peak gain

+11.5%

peak, from the publication price — not a realized return

S&P 500, same window

+3.3%

SPY over the identical days, dividend-adjusted

Window close

$68.67

last close inside the window, ended January 19, 2026

Peak price

$70.66

peak on January 15, 2026 — not a realized return

Days to target

—

The thesis — published October 21, 2025

Predicted growth

+18%

over the measurement window

Target price

$74.68

the price the thesis aimed for

Entry zone

$61.83 – $63.83

the fair-value band we waited for

Price at publication

$63.37

published October 21, 2025

Confidence

62%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Bio-Techne shows a strengthening trend: lots more people are buying than usual, and the price is above its recent average. A new global distribution deal with Saguaro could widen reach, and shares rose about 20% last month. Risks remain because core sales growth looks muted. This is a short-term idea: consider buying small dips only if trading volume stays strong, aiming for a 0-3 month drift higher.

Primary drivers

New global distribution deal with Saguaro may meaningfully expand reach
Buying interest is rising and price is above its recent average
Stock jumped 20% last month, showing strong demand from investors
Core sales growth appears soft, so near-term results may be uneven

How it played out

TECH: thesis partly played out, target missed

Lyra published TECH on 2025-10-21 at $63.37 with an 18% expected gain and a $74.68 target. The thesis pointed to rising buying interest, a price above its recent average, a new global distribution deal with Saguaro, and a 20% jump last month. It also flagged soft core sales growth as a risk.

Inside the window, TECH rose but did not reach $74.68. The stock peaked at $70.66 on 2026-01-15, with an 11.5% gain, then ended at $68.67. The direction was right, but the target was missed. The thesis partly played out.

What happened during the window

On December 9, 2025, Bio-Techne announced the expanded launch and first shipment of its enhanced Leo System, saying it enabled up to 24 targets per sample. On December 11, 2025, Bio-Techne announced a collaboration with the Wyss Center Geneva to develop an automated workflow for RNA and protein detection in 3D specimens.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All TECH signals